Navigating Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory - Episode 11
The Evolving Landscape: CAR T and Future Therapies in Early-Stage R/R Myeloma
Panelists discuss the key toxicities influencing chimeric antigen receptor (CAR) T-cell therapy selection for early relapsed/refractory multiple myeloma (R/R MM), the transition to community care post treatment, strategies for managing toxicities, the future of CAR T in early R/R MM, and the impact of emerging data on treatment sequencing, along with insights from the DREAMM-7 and DREAMM-8 studies and improving the CAR T process in academic and community settings.
Video content above is prompted by the following:
- In your opinion, what does the future look like for CAR T in early R/R MM?
- How does emerging data impact your approach to treatment sequencing in early R/R MM?
- DREAMM-7, belantamab mafodotin plusVd in R/R MM after 1 prior LOT
- DREAMM- 8, Belantamab mafodotin plus Pd in R/R MM after 1 prior LOT
- What clinical pearls can you share on how the overall CAR T process can improve in both the academic and community setting?
Related Content:
